Popit company news

Popit is attending Slush 2023

/by
We're attending SLUSH 2023 Popit is attending SLUSH 2023

Popit is attending SLUSH 2023! Slush is one of Europe’s largest startup events taking place every year in Helsinki, Finland. This year it brings over 10 000 attendees and several billions in VC capital. We will be attending the 2-day startup fest along with its plethora of side events.

What does Popit do, you may ask?

We’re on a mission to make managing meds as easy as reaching for a KitKat during a break. Our magic combination of a smart medication tracker and a user-friendly app takes the hassle out of the equation, giving patients much-needed peace of mind in their daily routines. Our solution is making waves worldwide, having made its mark across Europe, Japan, and even Down Under, all thanks to our strategic pharma partnerships.

If you would like to meet, please get in touch with us or book a meeting via the Slush Matchmaking tool.

Hope to see you there!

Popit and MediService join forces to transform how Swiss patients take medications

/by

Patient taking medication using Popit adherence solution

Popit and MediService join forces to transform how Swiss patients take medications.

Espoo, Finland – Popit, a pioneer in improving medication adherence, and MediService, a Swiss specialty pharmacy, are joining forces to revolutionize medication adherence for patients in Switzerland. In this collaboration, the Swiss pharmacy with a focus on caring for people with chronic and rare diseases will offer Popit to their patients taking anticoagulants to further improve adherence and patient outcome.

This exciting collaboration combines Popit’s innovative medication adherence technology with MediService’s longstanding expertise in home pharmacy care. The partnership underlines the ongoing change seen in treatment: medication-taking is becoming digital and patients increasingly expect new, convenient telehealth services.

The goal of this project is to empower patients to take even more control of outcomes. For this, Popit and MediService provide patients with a practical digital tool that not only brings unparalleled convenience and ease to their daily medication regimen but also removes the burden of worry and uncertainty. This way patients can focus on living their best lives with the peace of mind they deserve.

Anticoagulants are used for chronic cardiovascular conditions that are some of the leading causes of death and disability worldwide. In the EU only, about 9% of cases of cardiovascular disease (CVD) could be attributed to the fact that only about half of CVD patients consistently take prescribed life-saving medications.  Rivaroxaban is the active ingredient in the blood thinner medication that is commonly used to treat such conditions. It’s taken orally in regular intervals and, like any medication for chronic conditions, relies on patients taking it as prescribed for it to achieve the expected outcome.

Patients prescribed with rivaroxaban will be offered free of charge Popit’s small sensor device and mobile app that seamlessly track and remind them of their daily medication by using patented technology. Additionally, they will receive timely and personalized messages on the app, and in-app access to resources to stay educated and motivated with the treatment. With the help of Popit, patients will be able to prevent missed doses and achieve better treatment outcomes.

At Popit, we understand that managing a chronic condition can be challenging for patients. – Timo Heikkilä, COO of Popit

“That’s why we’re thrilled to partner with MediService to offer our cutting-edge technology to patients in Switzerland taking anticoagulants,” says Timo Heikkilä, COO. “We believe that everyone deserves the best possible health outcomes, and our technology can help patients stay on track with their medication regimen, avoid missed doses, and achieve better health. By working together, we’re putting patients at the center of their care and empowering them to take control of their health and well-being.”

For more information about the release, please contact Timo Heikkilä, +358(0)504873728.

 

About Popit

Popit is a pioneer in improving patient adherence through smart pill-tracking devices. The Company is dedicated to improving adherence by digitalizing medication, a major opportunity that benefits patients, patient support programs, healthcare payors, and the pharmaceutical industry. Popit works with the world’s leading pharmaceutical companies in executing this vision.

For more information, go to https://popit.io/

 

About MediService

At MediService, we have made it our mission to make life easier for chronic disease patients at home: Healthy@Home! In addition to the delivery of prescription medication, we also provide various specialized services, access to health knowledge, and tips and tricks on how to integrate medicines into everyday life.

You can find more information at https://www.mediservice.ch/de/ 

 

Popit featured in Japanese media

/by

 

Popit in TV Tokyo Femtech Committee

Popit media coverage in Japan. Popit was featured in TV Tokyo’s Femtech Committee.

Popit featured in TV Tokyo YouTube series, “Femtech Committee”

Popit media coverage in Japan!

Popit’s unique medication tracking device and app was featured in a YouTube series called “Femtech Committee” by TV Tokyo. TV Tokyo is one of the major TV broadcasters in Japan.

The program was launched with the aim of openly discussing topics related to women’s sexuality and health, which was considered somewhat taboo. It also aims to convey a positive image of Feminine health and well-being. Furthermore, it offers useful information that may come in handy right away, as well as content that addresses concerns that are unique to women.

In this episode, the host introduced our product as a unique and state-of-the-art Femtech tool for women on contraceptive pills. Popit supports them in keeping track of their daily pill doses, allowing them to minimize the chance of unintended pregnancy.

Link to the YouTube video (Note: The video is accessible within Japan only.)

Femtech in Japan:

In Japan, the Femtech trend is gaining momentum as more women seek out innovative solutions to address their unique health needs. There is an increasing amount of media coverage on different types of Femtech technology.

One area where Femtech is particularly popular in Japan is fertility tracking. There are several apps and devices available that allow women to track their menstrual cycles, monitor their ovulation, and increase their chances of getting pregnant. In addition, there are also products like pelvic floor trainers and breast pumps that are designed specifically for women’s bodies.

The Femtech trend in Japan is helping to empower women by giving them more control over their health and wellness. With continued innovation and investment, the industry is poised to grow in the years ahead, providing even more options for women to take charge of their health.

 

 

See you at Slush’22?

/by

blank

Photo © Petri Anttila

 

Slush 2022 brings to Helsinki 4 600 startup founders and operators, accompanied by 2 600 investors.  We’ll be there. How about you?

The Slush 2022 event features two days full of stage programs in addition to several Side Events, mentoring, meetings, and afterparties (duh).

Get in touch, if you’d like to meet while there, or book a meeting via the Slush Matchmaking tool.

Popit now certified in Australia

/by

Popit continues to expand to new markets. The latest market launch is happening in Australia, where Popit is now allowed to carry the local RCM mark.

Read more

Will you be at the Bits & Pretzels HealthTech Conference?

/by

Bits & Pretzels Healthtech Conference

Photo © Andreas Gebert

 

On 29–30 June 2022, the first annual Bits & Pretzels HealthTech Conference will take place at ICM Munich. We’ll be there. How about you?

With over 2 500 startups and 500 speakers the event is a focused gathering of digital health and MedTech founders and enthusiasts.

Get in touch, if you’d like to meet.

Open position: Digital Operations Market Manager

/by

UPDATE: This position has been filled. To hear first about our new positions, follow us on LinkedIn.

—–

Are you a self-driven professional with a strong track record in getting things done? Do you have a flair for content creation and analytics? Would you be interested in launching a unique digital health solution on new markets? Well look no further and get in touch!

Popit is a pioneering Finnish startup and we make medication digital. By doing so we improve medication adherence and help patients get the best possible medical treatment outcome. We’re big on making things happen and small on hierarchy. Popit works with the world’s largest pharmaceutical companies in Europe and Japan and our goal is to make a positive impact on the treatment of as many patients as possible. We support the United Nations Development Goal number 3 – Good Health and Wellbeing.

We are looking for a creative and analytical Digital Operations Market Manager (DOMM) to work with our pharma customers in introducing Popit to patients on new markets. The person we have in mind is a great communicator who can coordinate a project efficiently. S/he also knows how to create content, interpret data and draw conclusions from it and be a creative problem solver at heart.

What you would be doing:

  • Influence and create patient and healthcare professional (HCP) facing materials for new markets (such as onboarding materials, ads, flyers, video tutorials, webinars, blog posts, etc.).
  • Coordinate with PMs of respective markets to provide sales and onboarding materials, localize content and gather feedback on the content effectiveness.
  • Provide product training and onboarding support to local pharma customer reps and
  • Analyze and report the performance and success of rolled out campaigns and materials.
  • Data points to use: pharma customer feedback, patient feedback, Popit Solution data, Anonymous app data analytics.
  • Identify new marketing strategies and channels to enable growth.

Ideally, you have

  • 4+ years experience in project management/coordination
  • Hands on experience with Excel and analytics tools
  • Hands on experience with graphics tools, such as InDesign, Illustrator and Photoshop (or similar).
  • Excellent communication and interpersonal skills with a knack for understanding communication in different cultures
  • Creative and persistent problem-solving approach and customer-centric thinking
  • Entrepreneurial spirit
  • Desire to learn new things and not be afraid to go outside your comfort zone.
  • Professional fluency in English. Other languages – especially Japanese – considered a plus
  • Experience from pharma or health tech industry considered a plus

We offer

  • A challenging key role in a truly international company.
  • An opportunity to make a real impact on the lives of patients.
  • A possibility to grow with the company and build this into a team lead role. You get to influence the direction.
  • Competitive salary.
  • Work flexibility – We expect to see you at our office frequently (when things normalize, of course), but you can also work from home.
  • We’re still a company that’s growing up, so don’t expect a La Pavoni espresso machine or weekly fruit basket deliveries. They’re coming somewhere down the line, but right now we’re focusing on doing the right things for the business. We have two excellent restaurants in the building though and you do get lunch benefits. Oh and a free gym too, so you don’t have to spend time commuting to get those rock-hard abs :)

Employment Type

Full-time

How to apply

Apply through LinkedIn.

 

Popit and Ashfield Engage Partner To Improve Patient Adherence

/by

Ashfield Engage and Popit partner to improve patient adherence through supplemental real-time personalized support.

Ashfield Engage, part of UDG Healthcare plc, today announces it has partnered with Popit, a digital health company, to improve patient adherence in oral solid dosage (OSD) treatments and advance supplemental personalized patient support.

The collaboration brings together Popit’s novel monitoring technology, and Ashfield Engage’s patient support programs, to proactively respond to patients’ needs and tailor their reminders accordingly.

The Popit Sense™ device is attached to a pill sheet and uses patented technology to monitor missed doses and send alerts to patients via a smartphone app. The data is also transmitted to healthcare providers and support partners such as Ashfield Engage. Now enriched with this real-time data, Ashfield Engage can easily identify which patients require extra support.

As well as providing support through the app, Ashfield Engage will leverage its expert call center teams to reach out to patients to discuss any challenges with their medication.

We can engage with patients in a way that was previously not possible.

Ian Riches, Global Vice President, Patient Solutions at Ashfield Engage, explained:

“Prior to Popit’s technology, a large group of OSD patients were not getting the support they needed. While the majority of patients are adherent, those with a need for support can now be quickly identified and we can engage with them in a way that was previously not possible, which is really exciting.

“While typically patient data is only collected up to the point of prescription, we can now support patients throughout their treatment in real-time. By partnering with Popit we have a digital solution that enables rapid, personalized support to increase patient adherence and significantly improve patients’ health and wellbeing in the long term.”

Popit Sense technology is already being leveraged by many large pharmaceutical organizations, including Pfizer, Almirall and Novartis.

We see this as a really important step towards building better, more connected healthcare solutions that truly benefit patients’ health.

Timo Heikkilä, COO and Co-Founder of Popit, added: “Our solution provides a wealth of invaluable data for healthcare providers, and pharmaceutical organizations and we have seen excellent results following its adoption.

“By partnering with Ashfield Engage, we can now advance that service, and provide not only the data, but the direct follow up support to those patients in need. We are thrilled about this collaboration and look forward to supporting the large patient population reliant on OSD treatments. We see this as a really important step towards building better, more connected healthcare solutions that truly benefit patients’ health.”

To find out more about how Ashfield Engage and Popit Sense can benefit your organization, your product and your patients, visit: https://ashfieldengage.com/

To learn more about Popit, visit: https://popit.io/.

Contact Information

Lara Lovenbury, ramarketing | lara@ramarketingpr.com | +44 773 268 1275

About Popit

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitalizing medication, a major opportunity that benefits patients, patient support programs, healthcare payors and the pharmaceutical industry. Popit works with the world’s leading pharmaceutical companies in executing against this vision.

For more information, go to https://popit.io/

Popit Media contact: 

Timo Heikkilä
Co-founder & COO
Phone: +358 50 487 3728
timo@popit.io

About Ashfield

Ashfield, part of UDG, is an integrated healthcare services partner, offering a breadth of services across strategic consulting, benchmarking, commercialization, customer engagement, events, marketing and communications.

Ashfield comprises of three clearly defined, integrated business units: Ashfield Advisory, Ashfield Engage and Ashfield Health. Together, the Ashfield team uses imagination, strategy and action to redefine and deepen client partnerships, reimagine health and improve lives.

Ashfield   has   carefully   curated   its   business   through   the   acquisition   of   22 companies and is committed to offering streamlined services to best meet its clients’ needs. With a presence in more than 50 countries, over 7,000 employees strive to provide best-in-class service for more than 300 clients, including the top 30 global pharmaceutical companies.

For more information, go to www.oneashfield.com

About Ashfield Engage

Ashfield Engage, part of UDG Healthcare plc, is an expert, global partner in customer strategy and execution. Ashfield Engage helps clients connect with all healthcare audiences to ensure people get knowledge, support and medicines when and where they need them. As experts in strategic engagement, Ashfield Engage creates personalized, impactful experiences, across all channels. Every program is underpinned by human connections, omnichannel engagement and adaptive analytics.

Ashfield Engage has over 20 years’ experience with a team of over 5,000 employees, delivering services in more than 50 countries. Offering services across Medical Affairs, Market Access, Commercial, Patient Solutions and Event Experiences, Ashfield Engage helps its clients to engage with their stakeholders across the whole commercialization journey. Under the Ashfield umbrella, Ashfield Engage sits alongside Ashfield Advisory and Ashfield Health.

For more information, go to https://ashfieldengage.com/

Popit And Almirall Start Offering New Support Tool To Help Psoriasis Patients

/by

The Finnish digital health startup launches together with the biopharmaceutical company focused on skin health, first in The Netherlands.

HELSINKI, FINLAND / BARCELONA, SPAIN – NOVEMBER 12th, 2020

Finnish digital health startup Popit and Almirall, a global biopharmaceutical company focused on skin health have started a collaboration to provide a novel support solution for patients with psoriasis. Popit’s innovative solution is available for patients using the Skilarence® (Dimethyl fumarate) medication, used for treatment of moderate-to-severe plaque psoriasis. The solution improves medication adherence and offers support for the patient. The partnership has started with the first patients already using Popit in The Netherlands.

Psoriasis is a chronic, non-contagious skin disease with symptoms that include clearly defined red patches (“plaques”), scaly skin and often itching. It is estimated that 125 million people worldwide – or 2 to 3 % of the population – have psoriasis1. The condition has a profound impact on patients: nearly 60 % of people with psoriasis reported their disease to be a large problem in their everyday life2.

Skilarence® (Dimethyl fumarate) is a systemic treatment taken orally for psoriasis3. As with all medications, if patients are not taking it according to guidance, they also do not receive the best possible treatment outcomes. Popit helps patients stay on track with the treatment and gain access to tailor-made content on their therapy.

The innovative solution consists of a unique device that automatically tracks when a medication is taken, as well as an accompanying app that reminds only if a dose has been missed. The patient also receives useful support messages and psoriasis content tailored specifically for them. Popit has been clinically validated to significantly reduce missed doses4 and is already used by some of the largest pharmaceutical companies in the world with great results.

In the words of Francesca Wuttke, Chief Digital Officer of Almirall:

“We are pleased to be collaborating with Popit to bring novel adherence and engagement solutions to patients with psoriasis. As a result of this partnership we are able to provide a new patient experience through digital psoriasis treatment to inform, educate, manage expectations, and motivate our patients. Making our medicines connected is a huge leap for patients and the industry and we’re excited to be doing it with Popit”.

Teemu Piirainen, Popit’s CEO weighs in:

“There is a great need to improve medication adherence and patient support in psoriasis care. Popit can really help in this by tackling some of the most common causes for why doses are missed, which include forgetting the daily doses and insufficient awareness of how missed doses impact treatment outcomes. Additionally, the patient might face quite practical challenges with their treatment, like up-titration or predetermined changes in product strength, which may not always be easy to master. Popit supports the patient with these challenges.”

 

About Popit:

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitizing medication, a major opportunity that offers benefits for patients, healthcare payors and pharmaceutical companies. Popit works with the world’s leading pharmaceutical companies.

For more information, please visit popit.io

 

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (BME: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

 

Almirall media contact:

Communications Agency: Tinkle
Pilar Colomer
pcolomer@tinkle.es
Phone: (+34) 93 93 545 0861

Almirall Communications contact:
Francesca Wuttke
francesca.wuttke@almirall.com

Popit Media contact: 

Timo Heikkilä
Co-founder & COO
Phone: +358 50 487 3728
timo@popit.io

References:

  1. Psoriasis.org (https://www.psoriasis.org/psoriasis-statistics/)
  2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
  3. European Medicines Agency (https://www.ema.europa.eu/en/documents/overview/skilarence-epar-summary-public_en.pdf)
  4. DOI: 10.15761/COGRM.1000217

Popit Develops Research Tool for COVID-19 Treatment

/by

The telehealth startup’s platform streamlines the global effort of finding a treatment for COVID-19.

HELSINKI, FINLAND, MAY 7TH, 2020

Finnish MedTech and telehealth startup Popit has released a research extension that makes its platform an efficient tool for finding a treatment for COVID-19. The new enhancement called POPIT INSIGHTS™ provides unprecedented real-time data on how the medications being researched are taken. At the same time data quality is improved, since patients in the study take their medications more consistently thanks to Popit’s clinically validated adherence improvement impact. The new tool basically reduces missed pills and makes studies faster. Popit already has partners for the new product and is kicking off with first studies.

As the COVID-19 pandemic rages on, the world’s scientific community has come together in an exceptional way. New studies to chart out possible treatments are constantly starting. Today, on May 7th, there are nearly 800 listed COVID-19 studies either starting or already active around the globe.1

Getting patients to take the study medications in a timely manner is highly important for research success.

On average each study has over 500 patients, biggest ones having over 40 000 participants. Getting all these patients to take the study medications in a timely manner is highly important for research success – and also for the patients themselves to benefit from the treatment. Considering the gravity of the matter it is surprising that only 43% of study patients may be adherent.2 Reminding the rest of the patients to take their medications and simply having data on if those medications were actually taken or missed have not been a part of the researchers’ toolbox.

Popit is now changing that with POPIT INSIGHTS™, an extension to the company’s existing medication adherence platform already used by the world’s largest pharmaceutical companies, such as Novartis and Pfizer. The new solution offers a way to monitor how medication is being consumed, remind the patient if necessary, and gather study data remotely and in real time. On top of that the deployment is easy and quick.

The researchers were struggling with the same problems we already had a tool for.

Teemu Piirainen, Popit’s CEO explains further: “The company and our initial product were created on the foundation that we want to make medication connected. When the COVID situation escalated, we started to think of ways to refine our existing solution already used by pharma to serve the research community as well. The researchers were struggling with the same problems we already had a tool for: how to get the patient to take medications better and a sophisticated way to remotely and securely get data on if the medication was taken or not.”

First partners who sign up get the tools at a zero cost.

“It just seemed like something we had to build. And now it’s available. Anyone who is starting a medication study right now should get in touch with us. We want to contribute and the first partners who sign up get the tools at a zero cost. This is our way of pitching in and we’re already starting on different continents”, continues Piirainen.

Important request

While in some parts of the world the pandemic is starting to be more controllable, Popit requests to take extra care not to miss personal medications at this time, as up to 10% of hospitalizations are due to missing regular doses3. The admissions resulting from this poor adherence cause needless burden on the already heavily strained healthcare system. Medication can only work if it’s taken.

 

About Popit:

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitizing medication, a major opportunity that offers benefits for patients, healthcare payors and pharmaceutical companies. Popit works with the world’s leading pharmaceutical companies.

Media contact: Timo Heikkilä, Co-founder

Email: timo popit io

Web: https://popit.io/popit-adherence-kit-for-medication-research/

Twitter: https://twitter.com/popitmed

Facebook: https://www.facebook.com/popitmed

LinkedIn: https://www.linkedin.com/company/popit-ltd/

Instagram: https://www.instagram.com/popitmed

 

References:

1. https://covid-trials.com/
2. Osterberg L, Blaschke T. N Engl J Med. 2005;353:487–97
3. https://www.ncbi.nlm.nih.gov/pubmed/29666309